Mihaela Georgescu

Dr. Mihaela Georgescu


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2016 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
MGMihaela Georgescu
Mihaela Georgescu
IGIrina Gheorghe
Irina Gheorghe
Carmen CurutiuCarmen Curutiu
Carmen Curutiu
Veronica LazarVeronica Lazar
Veronica Lazar
Coralia BleotuCoralia Bleotu
Coralia Bleotu
Carmen ChifiriucCarmen Chifiriuc
Carmen Chifiriuc
The purpose of this study was to evaluate the virulence profiles of Pseudomonas aeruginosa clinical strains recently isolated from patients hospitalized for chronic leg ulcers in the Dermatology Department of Central Military Emergency University Hospital “Carol Davila”, Bucharest, Romania. The phenotypic screening evaluated eight soluble virulence factors (haemolysins, lecithinase, lipase, caseinase, gelatinase, amylase, DNase, aesculin hydrolysis), as well as adherence ability (Cravioto adapted method) and invasion capacity on HeLa cells (gentamicin protection assay). Seven virulence genes encoding for protease IV, 3 exoenzymes (exoS, exoT, exoU), two phospholipases plcH- haemolytic phospholipase C and plcN- non-haemolytic phospholipase C) and alginate were investigated by PCR. The pore forming toxins and enzymes were expressed in variable proportions, the majority of the tested strains producing beta haemolysin (92.3 %), lipase (76.9 %) and lecithinase (61.5 %). The most frequent virulence genes detected in the analyzed strains were the ExoT (100 %) and AlgD (92.3 %) genes, genes codifying for phospholipases (84.6 % each of them) and for protease IV (61.5 %). This study reveals that correlating virulence profiles and infection clinical outcome is very useful for setting up efficient preventive and therapeutic procedures for hospitalized patients with chronic leg ulcers and positive P. aeruginosa cultures.

Verified
Journal Article
Open access
PDF file
Daniel Octavian CostacheDaniel Octavian Costache
Daniel Octavian Costache
OFOana Feroiu
Oana Feroiu
AGAdelina Ghilencea
Adelina Ghilencea
MGMihaela Georgescu
Mihaela Georgescu
Ana CaruntuAna Caruntu
Ana Caruntu
RCRaluca Simona Costache
Raluca Simona Costache
The systemic inflammatory syndrome concept is one of the foundations that stand at the basis of revolutionary modern and future therapies, based on the in-depth understanding of the delicate mechanisms that govern the collaboration between the systems and organs of the human body and, at the same time, the fine balance that ensures a reproach-free operation. An interesting concept that we propose is that of the environment-inadequacy status, a concept that non-specifically incorporates all the situations of the organism’s response disorders in the face of imprecisely defined situations of the environment. The correlation between these two concepts will define the future of modern medicine, along with the gene-adjustment mechanisms. Psoriasis is a clear example of an inadequate body response as a result of exposure to as of yet undefined triggers with an excessive systemic inflammatory reaction and hitherto insufficiently controllable. Modern biological therapies, such as TNF-α, IL-12 family, and IL-17 inhibitors, are intended to profoundly reshape the cytokine configuration of patients with inflammatory diseases such as psoriasis, with tremendous success in disease control. Yet, because of the important roles of cytokines in cancer promotion and control, concern was raised about the fact that the use of biologicals may alter immune surveillance and promote cancer progression. Both theoretical and practical data nevertheless showed that the treatment-induced control of cytokines may be beneficial for reducing the inflammatory milieu that promotes cancer and such have a beneficial role in maintaining health. We briefly present the intricate roles of those cytokine families on cancer control, with some debates on if their inhibition might or might not promote additional tumoral development.

30 April 2016 in Metals
Verified
Journal Article
Open access
PDF file
MRMarius Radulescu
Marius Radulescu
EAEcaterina Andronescu
Ecaterina Andronescu
Alina Maria HolbanAlina Maria Holban
Alina Maria Holban
Bogdan Stefan VasileBogdan Stefan Vasile
Bogdan Stefan Vasile
Iordache FlorinIordache Florin
Iordache Florin
Carmen ChifiriucCarmen Chifiriuc
Carmen Chifiriuc
The aim of this study was to develop a biocompatible coating for wound dressings, containing iron oxide nanoparticles functionalized with patchouli essential oil in order to obtain improved antimicrobial properties able to prevent biofilm development and consecutive associated infections. The bioactive coating was prepared by the co-precipitation of a precursor in an alkaline solution of patchouli oil. The prepared surface was characterized by XRD (X ray diffraction), TEM (transmission electron microscopy), SAED (selected area diffraction), SEM (scanning electron microscopy) and FT-IR (Fourier transform infrared spectroscopy). The bioevaluation of the obtained coating consisted in antimicrobial, as well as in vitro and in vivo biocompatibility and biodistribution assays. The obtained coating revealed a strong anti-biofilm activity maintained up to 72 h, as well as a low cytotoxicity on mammalian cells and a good biodistribution after intraperitoneal injection in mice. These results demonstrate the promising potential of the respective coatings for the management of wound infections and for the development of soft materials with improved resistance to microbial colonization.

22 September 2023 in Cellulose
Verified
Journal Article
Open access
PDF file
IMIoana Cristina Marinas
Ioana Cristina Marinas
Gratiela GRADISTEANU PircalabioruGratiela GRADISTEANU Pircalabioru
Gratiela GRADISTEANU Pircalabioru
Eliza OpreaEliza Oprea
Eliza Oprea
Elisabeta-Irina GeanaElisabeta-Irina Geana
Elisabeta-Irina Geana
IZIrina Zgură
Irina Zgură
Carmen ChifiriucCarmen Chifiriuc
Carmen Chifiriuc
This study aimed to exploit two invasive plant species to develop a novel, multifunctional, bioactive wound dressing based on a microporous cellulosic sponge (CS) from Gleditsia triacanthos pods and functionalizing them with Phytolacca americana fruit extract. The CS was functionalized, lyophilized, and characterized by Attenuated total reflectance–Fourier transform infrared spectroscopy, X-ray diffraction, scanning electron microscopy, contact angle, water absorption, and retention capacity. In addition, two parameters were evaluated in temporal dynamics: controlled release of phenolic compounds and antioxidant activities. The hemolytic index, blood clotting kinetics, lactate dehydrogenase release, and wound scratch assays proved their hemo- and biocompatibility, as well as their ability to promote cell proliferation and migration promoting-activity and to inhibit microbial growth. Furthermore, the obtained spongious material exhibited an anti-inflammatory effect by modulating the macrophages’ secretion profile of IL-6 and IL-10. In conclusion, the microporous cellulosic sponge obtained from G. triacanthos could be used as a vehicle to ensure the controlled release of bioactive principles with pro-wound healing activities extracted from invasive plants. Graphical

25 September 2023 in JEADV Clinical Practice
Verified
Journal Article
Open access
DADaniela Anghel
Daniela Anghel
MGMihaela Georgescu
Mihaela Georgescu
MPMarcela Poenaru
Marcela Poenaru
DODiana Maria Orleanu
Diana Maria Orleanu
GTGeorge Sorin Tiplica
George Sorin Tiplica
Secukinumab is a monoclonal antibody used to specifically inhibit pathologic interleukin‐17 and therefore effectively manage conditions like plaque psoriasis, psoriatic arthritis and ankylosing spondylitis. Although we know that antitumor necrosis factor molecules can cause paradoxical pustular psoriasis, a few case reports noted this reaction in patients treated with secukinumab. We report a case of a paradoxical drug reaction consisting of palmar pustular psoriasis in a female patient treated with secukinumab for spondyloarthritis.

8 January 2023 in Romanian Journal of Military Medicine
Verified
Journal Article
Closed access
RCRaluca S. Costache
Raluca S. Costache
MGMihaela Georgescu
Mihaela Georgescu
AGAdelina Ghilencea
Adelina Ghilencea
OFOana Feroiu
Oana Feroiu
STSorin G. Tiplica
Sorin G. Tiplica
Daniel Octavian CostacheDaniel Octavian Costache
Daniel Octavian Costache